Navidea, Cardinal Health deal

Navidea will sell its Lymphoseek tilmanocept imaging agent to Cardinal Health for oncology indications

Read the full 142 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE